Saverio Valentina, Ferrario Emanuele, Monzani Romina, Gagliardi Mara, Favero Francesco, Corà Davide, Santoro Claudio, Corazzari Marco
Department of Health Sciences, School of Medicine, and Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale, Novara, Italy.
Department of Health Sciences, School of Medicine, and Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale, Novara, Italy; Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Piemonte Orientale, Novara, Italy.
Redox Biol. 2025 Feb;79:103463. doi: 10.1016/j.redox.2024.103463. Epub 2024 Dec 9.
Ferroptosis is a recently characterized form of cell death that has gained attention for its roles in both pathological and physiological contexts. The existence of multiple anti-ferroptotic pathways in both neoplastic and healthy cells, along with the critical regulation of iron metabolism involved in lipid peroxides (lipid-ROS) production-the primary mediators of this cell death process-underscores the necessity of precisely controlling or preventing accidental/unwanted ferroptosis. Conversely, dysregulated iron metabolism and alterations in the expression or activity of key anti-ferroptotic components are linked to the development and progression of various human diseases, including multiple sclerosis (MS). In MS, the improper activation of ferroptosis has been associated with the progressive loss of myelinating oligodendrocytes (myOLs). Our study demonstrates that the physiological and maturation-dependent increase in iron accumulation within oligodendrocytes acts as a pro-ferroptotic signal, countered by the concurrent expression of AKR1C1. Importantly, MS-related neuroinflammation contributes to the down-regulation of AKR1C1 through miRNA-mediated mechanisms, rendering mature oligodendrocytes more vulnerable to ferroptosis. Together, these findings highlight the role of ferroptosis in MS-associated oligodendrocyte loss and position AKR1C1 as a potential therapeutic target for preserving oligodendrocyte integrity and supporting neuronal function in MS patients.
铁死亡是一种最近被描述的细胞死亡形式,因其在病理和生理环境中的作用而受到关注。肿瘤细胞和健康细胞中多种抗铁死亡途径的存在,以及参与脂质过氧化物(脂质活性氧)产生(这种细胞死亡过程的主要介质)的铁代谢的关键调节,强调了精确控制或预防意外/不必要的铁死亡的必要性。相反,铁代谢失调以及关键抗铁死亡成分的表达或活性改变与包括多发性硬化症(MS)在内的各种人类疾病的发生和发展有关。在MS中,铁死亡的不适当激活与髓鞘形成少突胶质细胞(myOLs)的进行性丧失有关。我们的研究表明,少突胶质细胞内铁积累的生理和成熟依赖性增加作为一种促铁死亡信号,被AKR1C1的同时表达所抵消。重要的是,MS相关的神经炎症通过miRNA介导的机制导致AKR1C1的下调,使成熟的少突胶质细胞更容易发生铁死亡。总之,这些发现突出了铁死亡在MS相关少突胶质细胞丢失中的作用,并将AKR1C1定位为保护MS患者少突胶质细胞完整性和支持神经元功能的潜在治疗靶点。